Abstract:IMPORTANCE Psychiatric disorders display high levels of comorbidity and genetic overlap, necessitating multivariate approaches for parsing convergent and divergent psychiatric risk pathways. Identifying gene expression patterns underlying cross-disorder risk also stands to propel drug discovery and repurposing in the face of rising levels of polypharmacy. OBJECTIVE To identify gene expression patterns underlying genetic convergence and divergence across psychiatric disorders along with existing pharmacological interventions that target these genes. DESIGN, SETTING, AND PARTICIPANTS This genomic study applied a multivariate transcriptomic method, transcriptome-wide structural equation modeling (T-SEM), to investigate gene expression patterns associated with 5 genomic factors indexing shared risk across 13 major psychiatric disorders. Follow-up tests, including overlap with gene sets for other outcomes and phenome-wide association studies, were conducted to better characterize T-SEM results. The Broad Institute Connectivity Map Drug Repurposing Database and Drug-Gene Interaction Database public databases of drug-gene pairs were used to identify drugs that could be repurposed to target genes found to be associated with cross-disorder risk. Data were collected from database inception up to February 20, 2023. MAIN OUTCOMES AND MEASURES Gene expression patterns associated with genomic factors or disorder-specific risk and existing drugs that target these genes. RESULTS In total, T-SEM identified 466 genes whose expression was significantly associated (z >= 5.02) with genomic factors and 36 genes with disorder-specific effects. Most associated genes were found for a thought disorders factor, defined by bipolar disorder and schizophrenia. Several existing pharmacological interventions were identified that could be repurposed to target genes whose expression was associated with the thought disorders factor or a transdiagnostic p factor defined by all 13 disorders. CONCLUSIONS AND RELEVANCE The findings from this study shed light on patterns of gene expression associated with genetic overlap and uniqueness across psychiatric disorders. Future versions of the multivariate drug repurposing framework outlined here have the potential to identify novel pharmacological interventions for increasingly common, comorbid psychiatric presentations.

Network-based drug repurposing for psychiatric disorders using single-cell genomics

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Scrank Infers Drug-Responsive Cell Types from Untreated Scrna-Seq Data Using a Target-Perturbed Gene Regulatory Network

Network-based drug repurposing for schizophrenia

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.

Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis

Genome-Wide Mendelian Randomization Reveals Genetically-Supported Drug Targets for Psychiatric Disorders

Mapping the Cellular Etiology of Schizophrenia and Diverse Brain Phenotypes

Use of gene regulatory network analysis to repurpose drugs to treat bipolar disorder

Transcriptome-Wide Structural Equation Modeling of 13 Major Psychiatric Disorders for Cross-Disorder Risk and Drug Repurposing

T-SEM of 11 Major Psychiatric Disorders: Identification of Gene Expression Patterns for Cross-Disorder Risk and Drug Repurposing

Drug repositioning based on network-specific core genes identifies potential drugs for the treatment of autism spectrum disorder in children

Brain cell-type shifts in Alzheimer's disease, autism, and schizophrenia interrogated using methylomics and genetics

Single-cell genomics and regulatory networks for 388 human brains

Unraveling Psychiatric Disorders through Neural Single-Cell Transcriptomics Approaches

Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders.

BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders

The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders

Connecting genomic results for psychiatric disorders to human brain cell types and regions reveals convergence with functional connectivity

Multiscale Topology in Interactomic Network: From Transcriptome to Antiaddiction Drug Repurposing